Sato Pharmaceutical Inc.

FDA Regulatory Profile

Summary

Total Recalls
8
510(k) Clearances
0
Inspections
3
Compliance Actions
0

Known Names

sato pharmaceutical co, sato pharmaceutical, sato pharmaceutical, co, sato pharmaceutical inc

Recent Recalls

NumberClassProductDate
D-0323-2020Class IIIMotion Sickness (meclizine hydrochloride) 25 mg tablets, 12-count box, Distributed by Sato PharmaceuOctober 1, 2019
D-0303-2020Class IIISankaijo BOTANICAL LAXATIVE (docusate sodium 8.33 mg and sennosides 1.36 mg) tablets, 150-count bottOctober 1, 2019
D-0325-2020Class IIIMotion Sickness Strips (meclizine hydrochloride) 25 mg strips, 8-count box, Distributed by Sato PharOctober 1, 2019
D-0324-2020Class IIIWAL-DRAM 2 (meclizine Hydrochloride) 25 mg tablets, packaged in a) 12 count (NDC 0363-1407-01, UPC 3October 1, 2019
D-0322-2020Class IIIZentrip (meclizine Hydrochloride), 25 mg strips, 8-strips per box, Distributed by Sato PharmaceuticaOctober 1, 2019
D-0856-2017Class IIDORAMA-NEO (naphazoline hydrochloride) Eye wash, packaged in 0.5 FL OZ (15mL) bottles, Manufactured February 16, 2017
D-0855-2017Class IISATO CLEAR (naphazoline hydrochloride) Redness Reliever Eye Drops, packaged in 0.5 FL OZ (15mL) bottFebruary 16, 2017
D-0854-2017Class IIOptic Splash (naphazoline hydrochloride) Eye Drops, packaged in 0.5 FL OZ (15mL) bottles, ManufacturFebruary 16, 2017